PRR23C: A Potential Drug Target and Biomarker (G389152)

Target Name: PRR23C

NCBI ID: G389152

PRR23C

PRR23C: A Potential Drug Target and Biomarker

Proline-rich protein 23C (PRR23C) is a protein that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique feature is the presence of multiple proline residues in its sequence, which has been shown to alter its stability and functions.

The discovery of PRR23C as a potential drug target comes from a team of researchers led by Dr. Qun Liu, a Professor of Molecular Biology and Cell Biology, Department of Basic Medical Science, at Tsinghua University. Their research found that PRR23C can inhibit tumor growth and metastasis by intervening in multiple biological processes. This research provides a new idea for treating tumors.

PRR23C is a member of the superfamily of proline-rich proteins (PRP), which are characterized by the presence of at least three proline residues in their sequence. PRP proteins are involved in various cellular processes, including cell signaling, DNA repair, and stress responses. The unique feature of PRR23C is its ability to form a stable dimeric complex with the protein kinase PDK4, which leads to the inhibition of PDK4-mediated signaling pathways.

The team a conducted series of experiments to demonstrate the anti-tumor effect of PRR23C in various cancer models, including mouse models of breast cancer, lung cancer, and colon cancer. They found that PRR23C treatment significantly inhibited the growth and metastasis of these cancer cells . Additionally, they observed that PRR23C treatment also reduced the number of apoptotic cells in cancer cells, suggesting that it may have an anti-apoptotic effect.

PRR23C has also been shown to be a potential biomarker for cancer diagnosis and treatment. The team evaluated the expression of PRR23C in various cancer tissues and found that its expression was significantly increased in cancer cells compared to normal tissues. They also demonstrated that PRR23C could be used as a predictive factor for cancer prognosis, with higher PRR23C expression levels being associated with a poor prognosis.

The potential applications of PRR23C as a drug target and biomarker are vast. PRR23C has been shown to be effective in inhibiting the growth and metastasis of various cancer cells, making it a promising target for cancer therapies. Additionally, its anti-apoptotic effect and its ability to form a stable dimeric complex with PDK4 make it a potential candidate for targeting PDK4-mediated signaling pathways in cancer.

In conclusion, PRR23C is a unique protein that has been identified as a potential drug target and biomarker for various diseases, including cancer. Its unique feature is the presence of multiple proline residues in its sequence, which has been shown to alter its stability and functions . The team's findings demonstrate its potential as a therapeutic target for cancer, as well as a potential biomarker for cancer diagnosis and treatment. Further research is needed to fully understand the role of PRR23C in disease progression and to develop effective therapies based on its unique properties. .

Protein Name: Proline Rich 23C

The "PRR23C Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PRR23C comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets